Related Experiment Video
Updated: Sep 3, 2025
06:39
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
9.9K
Myelodysplastic Syndrome: Diagnosis and Screening
Francisco P Tria1, Daphne C Ang1, Guang Fan2
1Section of Cellular Immunology and Molecular Pathology, Institute of Pathology, St. Luke's Medical Center-Global City, Taguig 1634, Metro Manila, Philippines.
Diagnostics (Basel, Switzerland)
|July 27, 2022
Summary
Myelodysplastic syndromes (MDS) are clonal myeloid disorders with cytopenia and dysplasia. Diagnosis requires integrating clinical, laboratory, and Next Generation Sequencing findings due to a lack of specific biomarkers.
Area of Science:
- Hematology
- Oncology
- Molecular Diagnostics
Background:
- Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders.
- Characterized by peripheral blood cytopenias, bone marrow dysplasia, and risk of transformation to acute myeloid leukemia (AML).
- Recent advances in Next Generation Sequencing (NGS) and therapeutics have improved management.
Purpose of the Study:
- To review the current understanding of MDS diagnosis and management.
- To highlight the role of NGS in improving diagnostic accuracy.
- To emphasize the need for integrated diagnostic approaches.
Main Methods:
- Review of recent literature on MDS diagnosis and treatment.
- Analysis of the impact of NGS technologies on MDS diagnostics.
- Discussion of clinical and laboratory parameters in MDS diagnosis.
Main Results:
- NGS has enhanced the identification of genetic abnormalities in MDS.
- Improved prognostic stratification and therapeutic strategies are emerging.
- No single diagnostic parameter is specific for MDS.
Conclusions:
- Accurate MDS diagnosis relies on a comprehensive approach.
- Integrating clinical data, morphology, and molecular findings (NGS) is crucial.
- Further research is needed to refine diagnostic criteria and therapeutic targets.
